Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of enamel mineralization, the deposition of calcium salts in tooth enamel. [GOC:BHF, GOC:mah]
Positive regulation of enamel mineralization is a complex and tightly controlled process that involves a coordinated interplay of multiple cellular and molecular components. It is a crucial step in the formation of enamel, the hard, protective outer layer of teeth. Here's a detailed description of this biological process:
1. **Ameloblast Differentiation and Polarization:** The process begins with ameloblasts, specialized epithelial cells responsible for enamel formation. These cells undergo differentiation and polarization, acquiring distinct apical and basal poles. The apical pole faces the enamel matrix, while the basal pole interacts with the underlying dentin.
2. **Secretion of Enamel Matrix Proteins:** Mature ameloblasts secrete a complex matrix of proteins that forms the initial scaffold for enamel. These proteins include amelogenin, enamelin, and tuftelin, each with unique roles in enamel formation. Amelogenin, the most abundant protein, plays a crucial role in guiding the deposition of hydroxyapatite crystals, the mineral component of enamel.
3. **Hydroxyapatite Crystal Nucleation and Growth:** Within the enamel matrix, hydroxyapatite crystals begin to nucleate and grow. This process is initiated by specific proteins and ions present in the matrix, including amelogenin and calcium ions. The crystal growth is highly regulated and influenced by factors like pH, temperature, and the presence of other ions.
4. **Crystal Organization and Maturation:** As hydroxyapatite crystals grow, they align and organize into a highly structured, rod-like arrangement, known as enamel prisms. This organized structure contributes to the hardness and strength of enamel. The amelogenin proteins help guide and control the crystal organization, preventing uncontrolled growth and ensuring proper alignment.
5. **Amelogenin Removal and Crystal Maturation:** As the enamel matrix matures, amelogenin molecules are progressively removed by proteolysis, a process facilitated by specific enzymes. This removal allows for the close packing of hydroxyapatite crystals and contributes to the final hardness of enamel.
6. **Final Enamel Maturation:** The last stage involves the maturation of enamel, which entails further crystal growth, organization, and mineral deposition. This stage leads to the formation of a highly mineralized, protective enamel layer, which is resistant to wear and tear.
7. **Regulation of Enamel Mineralization:** Several factors regulate enamel mineralization, including genetic factors, dietary intake, and signaling pathways. For example, the expression of genes involved in ameloblast differentiation, protein secretion, and crystal formation is crucial for proper enamel development. Signaling molecules, such as bone morphogenetic proteins (BMPs) and fibroblast growth factors (FGFs), also play significant roles in regulating ameloblast function and enamel mineralization.
In conclusion, positive regulation of enamel mineralization is a complex and precisely coordinated process involving ameloblast differentiation, protein secretion, hydroxyapatite crystal nucleation and growth, crystal organization, amelogenin removal, and final enamel maturation. Understanding the intricate mechanisms underlying this process is essential for developing strategies to prevent and treat dental disorders, including enamel defects and tooth decay.'
"
Protein | Definition | Taxonomy |
---|---|---|
Cystic fibrosis transmembrane conductance regulator | A cystic fibrosis transmembrane conductance regulator that is encoded in the genome of human. [PRO:CNA, UniProtKB:P13569] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
glyburide | glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide | monochlorobenzenes; N-sulfonylurea | anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent |
methyl anthranilate | methyl anthranilate : A benzoate ester that is the methyl ester of anthranilic acid. | benzoate ester | flavouring agent; metabolite |
telmisartan | telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension. Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION. | benzimidazoles; biphenyls; carboxybiphenyl | angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic |
tadalafil | benzodioxoles; pyrazinopyridoindole | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent | |
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine | |||
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone | 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone: a cystic fibrosis transmembrane conductance regulator inhibitor; structure in first source | ||
uccf-029 | organic heterotricyclic compound; organooxygen compound | ||
quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
apigenin | Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia. | trihydroxyflavone | antineoplastic agent; metabolite |
rutin | Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders. | disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone | antioxidant; metabolite |
genistein | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | |
vx-770 | ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis. ivacaftor: a CFTR potentiator; structure in first source | aromatic amide; monocarboxylic acid amide; phenols; quinolone | CFTR potentiator; orphan drug |
lumacaftor | lumacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxylic acid with the aromatic amino group of 3-(6-amino-3-methylpyridin-2-yl)benzoic acid. Used for the treatment of cystic fibrosis. lumacaftor: a corrector of CF transmembrane conductance regulator (CTFR); structure in first source | aromatic amide; benzodioxoles; benzoic acids; cyclopropanes; organofluorine compound; pyridines | CFTR potentiator; orphan drug |